Pacific Edge Full Year Results to be Announced 29 May 2018

14 May 2018


PACIFIC EDGE FULL YEAR RESULTS TO BE ANNOUNCED 29 MAY 2018

Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year results for the financial year ended
31 March 2018 on Tuesday 29 May 2018, prior to 10am NZST.

This will be followed by an analyst and investor conference call with Pacific Edge Chief Executive, David Darling
and Chief Financial Officer, Kate Rankin. The conference call is scheduled to begin at 10.30am NZST.

To attend the conference call, participants will need to dial into one of the numbers below at least 5-10 minutes
prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the
confirmation code: 7186210.

The results presentation will be released to the NZX and can also be streamed live by following the link. Please
note that you need to dial in to hear the audio: https://slideassist.webcasts.com/starthere.jsp?ei=1193240

Media are invited to contact the company directly for an interview with management.

A recording of the conference call will be made available within 48 hours in the Investor section on the Pacific
Edge website.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley
on 03 479 5807 or stacey.stanley@pelnz.com.

Dial toll free from NZ: 0800 423 970
Dial toll free from Australia: 1800 573 793
Dial toll free from USA: 800 239 9838
Dial toll free from Singapore: 800 186 5107


ENDS

Approved for release by:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800



OVERVIEW www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. The company is
developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central
laboratories in New Zealand and the USA. The company’s products have been tested and validated in international multi-
centre clinical studies.

14 May 2018
Pacific Edge has four proprietary, novel, accurate, molecular diagnostic products in-market providing actionable results, and
better detection and management of urothelial cancer. Cxbladder Triage, Detect and Monitor are available through the
company’s dedicated CLIA-certified laboratories for customers in New Zealand, Australia, Singapore and the USA. Cxbladder
Resolve launched in New Zealand in December 2016.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a
low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect was launched in 2013 in the USA and is commercially available in New Zealand, Australia
and the USA as a Laboratory Developed Test (LDT) from the company’s CLIA certified laboratories. Cxbladder Detect provides
clinicians with a quick, cost effective and accurate measure of the presence of the cancer as an effective adjunct to
cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists, is a proprietary, non-invasive, molecular diagnostic
test that combines genomic biomarkers measured from a small quantity of a patient’s urine, with patient specific clinical
factors to better monitor bladder cancer patients for recurrence. Bladder cancer has a recurrence rate of 50-80% and
requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior history of urothelial cancer (UC)
whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial carcinoma. Cxbladder Monitor
is designed to be used as the preferred adjunct test to cystoscopy in the management of patients for ongoing evaluation of
recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve is a proprietary, non-invasive, molecular diagnostic test that combines genomic biomarkers measured
from a small quantity of a patient’s urine, with patient characteristics for the identification of patients who are likely to have
aggressive or more advanced bladder cancer. Cxbladder Resolve, when used as part of the primary evaluation of haematuria
and/or in conjunction with other Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying
patients with a high probability of having high grade or late stage bladder cancer, for whom alternative or expedited
treatment options may be warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.